Mechanism of Disease
This multimedia content is made available for HCPs specializing in oncology for learning and information purposes only to address the need of the medical community to better understand investigational interventions and the physiology of disease.
View material from GSK oncology on proposed mechanism of disease of various cancers.
Belantamab Mafodotin*
Anti-BCMA immunoconjugate
Learn about how belantamab mafodotin binds to B-cell maturation antigen and eliminates myeloma cells by a multimodal mechanism.
*In-license or other partnership with third party
Cobolimab
Anti-TIM-3 Antibody
Learn about Cobolimab a selective humanized anti-TIM-3 IgG4 monoclonal antibody that enhances T-cell activation.
Dostarlimab
Anti-PD-1 antibody
Learn about the programmed cell death protein 1 (PD-1), an immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cell-mediated immune response.
Niraparib
PARP inhibitor
Learn about the Poly ADP ribose polymerases (PARPs) family of enzymes which are involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. PARP inhibition induces cell death through synthetic lethality.
The CD226 Axis
TIGIT | CD96 | PVRIG
Understanding the Immune Enhancers of the CD226 Axis
Role of PD-1 inhibitor in CD226 Axis
How CD226 Axis and PD-1 Checkpoint Blockers May Work to Fight Cancer
Role of CD226 axis in cancer immunotherapy targets
Introduction to New Cancer Immunotherapy Targets
Rational for combining anti-PD-1 and PARPi in NSCLC
Learn more about combination of PARPi and anti-PD-1 in NSCLC
Brain metastasis and their role in metastatic NSCLC
Brain metastasis disease state
The Blood Brain Barrier and the ability of compounds to cross it
Learn more about blood brain barrier (BBB) and it’s role in drug delivery to brain
Blood Brain Barrier penetration by Niraparib
Learn more about Niraparib’s ability to cross the Blood Brain Barrier in animal models
Niraparib Ovarian Cancer Disease State 3D Video
Learn more about the ovarian cancer disease state
Momelotinib mechanism of action
JAK1, JAK2 and ACVR1 Inhibitor
Learn about how momelotinib inhibits key drivers of myelofibrosis: dysregulated signalling in the JAK-STAT pathway and hyperactivation of the ACVR1 pathway.
Combination Therapy MOA Video
Combination Therapy MOA Video
SE-GBL-ON-WCNT-200001 | November 2023